clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00118261 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | United States of America | Q30 |
P582 | end time | 2011-01-01 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 17 | |
P4844 | research intervention | leucovorin calcium | Q27077063 |
fluorouracil | Q238512 | ||
calcium oxalate | Q412399 | ||
bevacizumab | Q413299 | ||
P6153 | research site | MetroHealth Medical Center | Q30254005 |
Case Western Reserve University | Q1047060 | ||
P859 | sponsor | Case Comprehensive Cancer Center | Q39050124 |
P580 | start time | 2005-03-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab |
Search more.